• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Evvy Launches Prescription-Grade At-Home Treatments for Vaginal Health

by Jasmine Pennic 11/14/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Evvy, a female-founded vaginal microbiome company, is expanding access to science-backed women’s healthcare with the launch of new prescription-grade, at-home treatments for vaginal health. 

– These treatments offer fast-acting relief for common vaginal symptoms like pH imbalance, dryness, odor, and irritation.

Expanding Access to Vaginal Healthcare

This marks the first time patients can access Evvy’s prescription products without first taking the Evvy Vaginal Health Test, a significant step towards making effective vaginal healthcare more accessible. Patients can order treatments directly from Evvy’s website and will be matched with an Evvy-affiliated provider who can review their health information and prescribe the appropriate products.

Clean, Effective, and Non-Toxic Solutions

Evvy’s new line of at-home treatments includes:

  • Pure Boric Acid Suppositories: Balance vaginal pH and reduce odor and discomfort.
  • Hyaluronic Acid Suppositories: Provide hormone-free relief for vaginal dryness and pain with sex.
  • Anti-Itch Vulva Cream: Soothe external itching and inflammation.
  • Soothing Vulva Cream: Offer relief for external dryness and irritation.

These treatments are formulated with high-quality ingredients and are free of harmful chemicals like parabens, phthalates, and artificial fragrances. They are designed to provide fast-acting relief while patients await the results of their Evvy Vaginal Health Test or for those seeking immediate symptom management.

Advanced Vaginal Microbiome Testing

While the new treatments offer symptom relief, Evvy’s Vaginal Health Test remains a powerful tool for identifying the root cause of vaginal issues. This advanced test analyzes the vaginal microbiome, providing personalized insights and guiding patients towards targeted treatments to restore vaginal health.

Personalized Treatment Programs

Patients who take the Vaginal Health Test gain access to personalized treatment programs that may include a broader range of Evvy’s prescription treatments, such as antibiotics, antifungals, vaginal estrogen, and probiotics. These programs go beyond symptom relief to address underlying infections and rebuild a healthy vaginal microbiome.

Availability

Evvy’s Vaginal Health Test is available in all 50 states, while the new at-home treatments are currently available in 39 states with plans for expansion in 2025.

“Our new prescription product line will empower patients to manage their symptoms quickly and confidently while Evvy’s advanced testing gets to the root cause of their symptoms,” explains Priyanka Jain, co-founder and CEO of Evvy, “Once patients receive results from our world-leading vaginal microbiome test, we can go beyond symptom relief to deliver personalized care that supports long-term microbiome health for each patient.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Femtech

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |